Skip to main content

Dismissed Risperdal Gynecomastia Lawsuit Reinstated

Dismissed Risperdal Gynecomastia Lawsuit Reinstated

Dismissed Risperdal Gynecomastia Lawsuit Reinstated

Introduction

A 2013 Risperdal lawsuit, filed by a man and his mother against Johnson & Johnson (J&J) and its subsidiary Janssen Pharmaceuticals for failing to provide adequate warnings regarding Risperdal’s potential to cause gynecomastia, which was dismissed in 2016, has been reinstated.

According to court documents, the man started using Risperdal in 2004 at the age of 7 and continued using the powerful antipsychotic medication until he was 10 years old. While on Risperdal, he developed female-like breasts, a condition known as gynecomastia. The lawsuit was later dismissed under Texas law by Judge Sean F. Kennedy, stating plaintiffs’ expert witness provided insufficient testimony against Risperdal.

On Tuesday, a 3-judge-panel of the Pennsylvania Superior Court ruled that the case should be evaluated under Pennsylvania law since it was procedural, thereby remanded the case back to Philadelphia and ordered a new trial.

In May, the Pennsylvania Supreme Court examined the level of public awareness regarding the dangers of Risperdal, which can put potential plaintiffs on notice to investigate their claims.

Nearly 7,000 gynecomastia lawsuits are pending in the Pennsylvania mass tort program. Two coordinated actions have been filed for Risperdal cases: one in Los Angeles Superior Court (Risperdal and Invega Product Liability Cases, JCCP 4775, presided by Honorable William Highberger) and the other in Philadelphia (In Re: Risperdal Litigation, March 2010 Term, Case No. 100300296).

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!